JPS61263929A - 抗タイプ２インターフェロン感受性疾患剤 - Google Patents
抗タイプ２インターフェロン感受性疾患剤Info
- Publication number
- JPS61263929A JPS61263929A JP61100263A JP10026386A JPS61263929A JP S61263929 A JPS61263929 A JP S61263929A JP 61100263 A JP61100263 A JP 61100263A JP 10026386 A JP10026386 A JP 10026386A JP S61263929 A JPS61263929 A JP S61263929A
- Authority
- JP
- Japan
- Prior art keywords
- interferon
- type
- cells
- human
- animal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 201000010099 disease Diseases 0.000 title claims abstract description 29
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract description 29
- 102000008070 Interferon-gamma Human genes 0.000 title claims abstract description 27
- 108010074328 Interferon-gamma Proteins 0.000 title claims abstract description 27
- 238000004519 manufacturing process Methods 0.000 title claims description 59
- 102000014150 Interferons Human genes 0.000 claims abstract description 147
- 108010050904 Interferons Proteins 0.000 claims abstract description 147
- 229940079322 interferon Drugs 0.000 claims abstract description 146
- 241001465754 Metazoa Species 0.000 claims abstract description 46
- 239000003814 drug Substances 0.000 claims abstract description 23
- 239000002799 interferon inducing agent Substances 0.000 claims abstract description 15
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 6
- 206010028980 Neoplasm Diseases 0.000 claims description 18
- 229940124597 therapeutic agent Drugs 0.000 claims description 17
- 238000000338 in vitro Methods 0.000 claims description 14
- 238000001727 in vivo Methods 0.000 claims description 10
- 238000009792 diffusion process Methods 0.000 claims description 7
- 239000007788 liquid Substances 0.000 claims description 7
- 230000003449 preventive effect Effects 0.000 claims description 7
- 210000001124 body fluid Anatomy 0.000 claims description 6
- 239000010839 body fluid Substances 0.000 claims description 6
- 230000002554 disease preventive effect Effects 0.000 claims description 6
- 239000002671 adjuvant Substances 0.000 claims description 2
- 239000007787 solid Substances 0.000 claims description 2
- 239000003381 stabilizer Substances 0.000 claims description 2
- 239000004067 bulking agent Substances 0.000 claims 1
- 239000006072 paste Substances 0.000 claims 1
- 241000282412 Homo Species 0.000 abstract description 7
- 229940079593 drug Drugs 0.000 abstract description 6
- 108010062580 Concanavalin A Proteins 0.000 abstract description 3
- 241000282326 Felis catus Species 0.000 abstract description 2
- 239000000411 inducer Substances 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 120
- 230000000694 effects Effects 0.000 description 30
- 238000000034 method Methods 0.000 description 25
- 102000002227 Interferon Type I Human genes 0.000 description 20
- 108010014726 Interferon Type I Proteins 0.000 description 20
- 239000000243 solution Substances 0.000 description 14
- 238000011580 nude mouse model Methods 0.000 description 13
- 108010047620 Phytohemagglutinins Proteins 0.000 description 12
- 238000002474 experimental method Methods 0.000 description 12
- 230000001885 phytohemagglutinin Effects 0.000 description 12
- 238000002347 injection Methods 0.000 description 11
- 239000007924 injection Substances 0.000 description 11
- 239000002609 medium Substances 0.000 description 11
- 230000035755 proliferation Effects 0.000 description 11
- 230000003612 virological effect Effects 0.000 description 11
- 241000699800 Cricetinae Species 0.000 description 9
- 241000711408 Murine respirovirus Species 0.000 description 9
- 241000700605 Viruses Species 0.000 description 9
- 239000000725 suspension Substances 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- 241000699660 Mus musculus Species 0.000 description 8
- 230000016396 cytokine production Effects 0.000 description 8
- 230000002265 prevention Effects 0.000 description 8
- 238000002054 transplantation Methods 0.000 description 8
- 239000000203 mixture Substances 0.000 description 7
- 235000015097 nutrients Nutrition 0.000 description 7
- 239000002504 physiological saline solution Substances 0.000 description 7
- 239000000843 powder Substances 0.000 description 7
- 241000894007 species Species 0.000 description 7
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 6
- 230000028993 immune response Effects 0.000 description 6
- 239000010453 quartz Substances 0.000 description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicon dioxide Inorganic materials O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 6
- 206010003445 Ascites Diseases 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 241000700159 Rattus Species 0.000 description 5
- 230000035931 haemagglutination Effects 0.000 description 5
- 238000007920 subcutaneous administration Methods 0.000 description 5
- 210000004881 tumor cell Anatomy 0.000 description 5
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 4
- 102000016605 B-Cell Activating Factor Human genes 0.000 description 4
- 108010028006 B-Cell Activating Factor Proteins 0.000 description 4
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 4
- 210000000683 abdominal cavity Anatomy 0.000 description 4
- 235000013601 eggs Nutrition 0.000 description 4
- 238000002523 gelfiltration Methods 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 210000000265 leukocyte Anatomy 0.000 description 4
- 210000004698 lymphocyte Anatomy 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 230000002062 proliferating effect Effects 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 3
- 229910002092 carbon dioxide Inorganic materials 0.000 description 3
- 239000001569 carbon dioxide Substances 0.000 description 3
- 210000004748 cultured cell Anatomy 0.000 description 3
- 239000002158 endotoxin Substances 0.000 description 3
- 238000005194 fractionation Methods 0.000 description 3
- 238000004108 freeze drying Methods 0.000 description 3
- 210000005260 human cell Anatomy 0.000 description 3
- 230000008105 immune reaction Effects 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 230000002147 killing effect Effects 0.000 description 3
- 239000003226 mitogen Substances 0.000 description 3
- 102000039446 nucleic acids Human genes 0.000 description 3
- 108020004707 nucleic acids Proteins 0.000 description 3
- 150000007523 nucleic acids Chemical class 0.000 description 3
- 239000002674 ointment Substances 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 230000004565 tumor cell growth Effects 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 206010010741 Conjunctivitis Diseases 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- 102000004142 Trypsin Human genes 0.000 description 2
- 108090000631 Trypsin Proteins 0.000 description 2
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 2
- 238000011047 acute toxicity test Methods 0.000 description 2
- 210000004102 animal cell Anatomy 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 238000000502 dialysis Methods 0.000 description 2
- 239000003889 eye drop Substances 0.000 description 2
- 229940012356 eye drops Drugs 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 206010022000 influenza Diseases 0.000 description 2
- 210000004379 membrane Anatomy 0.000 description 2
- 239000007923 nasal drop Substances 0.000 description 2
- 229940100662 nasal drops Drugs 0.000 description 2
- 230000001613 neoplastic effect Effects 0.000 description 2
- 210000003200 peritoneal cavity Anatomy 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000001179 sorption measurement Methods 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000012588 trypsin Substances 0.000 description 2
- 238000000108 ultra-filtration Methods 0.000 description 2
- 241000271566 Aves Species 0.000 description 1
- 241000711404 Avian avulavirus 1 Species 0.000 description 1
- 235000003351 Brassica cretica Nutrition 0.000 description 1
- 235000003343 Brassica rupestris Nutrition 0.000 description 1
- 241000219193 Brassicaceae Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 241000272201 Columbiformes Species 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 208000005100 Herpetic Keratitis Diseases 0.000 description 1
- 241000701085 Human alphaherpesvirus 3 Species 0.000 description 1
- 241000701024 Human betaherpesvirus 5 Species 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- 241001175904 Labeo bata Species 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930192392 Mitomycin Natural products 0.000 description 1
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 1
- 206010073938 Ophthalmic herpes simplex Diseases 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- 208000005107 Premature Birth Diseases 0.000 description 1
- 206010036590 Premature baby Diseases 0.000 description 1
- 241000606701 Rickettsia Species 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 208000012544 Viral Skin disease Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 210000001691 amnion Anatomy 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 239000007640 basal medium Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 238000003795 desorption Methods 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 210000002257 embryonic structure Anatomy 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- -1 gargles Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000009422 growth inhibiting effect Effects 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 201000010884 herpes simplex virus keratitis Diseases 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 239000012510 hollow fiber Substances 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000014828 interferon-gamma production Effects 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 230000001678 irradiating effect Effects 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 229920006008 lipopolysaccharide Polymers 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 238000001471 micro-filtration Methods 0.000 description 1
- 229960004857 mitomycin Drugs 0.000 description 1
- 235000010460 mustard Nutrition 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 201000008968 osteosarcoma Diseases 0.000 description 1
- 229940066842 petrolatum Drugs 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 201000005404 rubella Diseases 0.000 description 1
- 238000005185 salting out Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 208000002254 stillbirth Diseases 0.000 description 1
- 231100000537 stillbirth Toxicity 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Landscapes
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP61100263A JPS61263929A (ja) | 1986-04-30 | 1986-04-30 | 抗タイプ２インターフェロン感受性疾患剤 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP61100263A JPS61263929A (ja) | 1986-04-30 | 1986-04-30 | 抗タイプ２インターフェロン感受性疾患剤 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP454479A Division JPS5598118A (en) | 1979-01-18 | 1979-01-18 | Preparation of type-2 interferon and drug containing the same |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS61263929A true JPS61263929A (ja) | 1986-11-21 |
| JPS6323176B2 JPS6323176B2 (enrdf_load_stackoverflow) | 1988-05-16 |
Family
ID=14269316
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP61100263A Granted JPS61263929A (ja) | 1986-04-30 | 1986-04-30 | 抗タイプ２インターフェロン感受性疾患剤 |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS61263929A (enrdf_load_stackoverflow) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS63198636A (ja) * | 1987-01-20 | 1988-08-17 | シェリング・コーポレーション | γ型インターフェロンとα型インターフェロンの組合せによる白血病の治療 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5562024A (en) * | 1978-10-31 | 1980-05-10 | Hayashibara Takeshi | Preventive and remedy for interferon-sensitive disease |
-
1986
- 1986-04-30 JP JP61100263A patent/JPS61263929A/ja active Granted
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5562024A (en) * | 1978-10-31 | 1980-05-10 | Hayashibara Takeshi | Preventive and remedy for interferon-sensitive disease |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS63198636A (ja) * | 1987-01-20 | 1988-08-17 | シェリング・コーポレーション | γ型インターフェロンとα型インターフェロンの組合せによる白血病の治療 |
Also Published As
| Publication number | Publication date |
|---|---|
| JPS6323176B2 (enrdf_load_stackoverflow) | 1988-05-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK169479B1 (da) | Fremgangsmåde til fremstilling af humanspecifikt type II-interferon | |
| US4276282A (en) | Interferon and preparations containing interferon | |
| JPS6227048B2 (enrdf_load_stackoverflow) | ||
| GB2083826A (en) | Process for the production of human insulin | |
| NO173144B (no) | Fremgangsmaate til fremstilling av interferongamma | |
| JPS61263929A (ja) | 抗タイプ２インターフェロン感受性疾患剤 | |
| JPS6011890B2 (ja) | ツモアネクロシスフアクタ−の製造方法 | |
| JP2926409B2 (ja) | 癌転移抑制因子の製造方法 | |
| JPS5816687A (ja) | リンホトキシンの製造方法 | |
| KR820001174B1 (ko) | 사람 특이성 인터페론의 제조법 | |
| KR830001817B1 (ko) | 타이프ⅱ 인터페론의 제조방법 | |
| RU2034565C1 (ru) | Биологически активный препарат для кур и способ профилактики и лечения вирусных заболеваний кур | |
| JPS5823793A (ja) | ヒトｔ細胞増殖因子の製造方法 | |
| JPH0764744B2 (ja) | 標的細胞障害性因子とヒトインタ−フェロンとを有効成分として含有する悪性腫瘍治療剤 | |
| JP2632849B2 (ja) | γ―インターフェロンの製造方法 | |
| US4994556A (en) | Novel lymphokine and its production and uses | |
| JPS5815921A (ja) | 抗リンホトキシン感受性疾患剤 | |
| JP2850293B2 (ja) | γ−インターフェロン感受性疾患剤 | |
| JPH0527640B2 (enrdf_load_stackoverflow) | ||
| JPH0526468B2 (enrdf_load_stackoverflow) | ||
| JPS61115026A (ja) | 新リンホカイン２の製造方法 | |
| JPS62223196A (ja) | 精製されたヒト ツモア・ネクロシス・フアクタ− | |
| JPH0811759B2 (ja) | 新リンホカイン▲ｉｉ▼とその製法および用途 | |
| JPS58320B2 (ja) | マウスインタ−フエロンの製造方法 | |
| JPH06316600A (ja) | 新リンホカインｉｉｉを有効成分とする新リンホカインｉｉｉ感受性疾患剤 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EXPY | Cancellation because of completion of term |